615
Views
79
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Prognostic significance of acute renal injury in acute tumor lysis syndrome

, , , &
Pages 221-227 | Received 02 Jul 2009, Accepted 01 Nov 2009, Published online: 09 Dec 2009
 

Abstract

Acute tumor lysis syndrome (ATLS) caused by the destruction of malignant cells leads to metabolic abnormalities, which may either remain isolated (biological ATLS) or subsequently lead to renal dysfunction (clinical ATLS). We compared hospital and 6-month survival in patients with ATLS with hematological malignancies with or without acute renal injury. Sixty-three patients (median age, 50 years; range, 32–64) were included with ATLS. Twenty-eight had no ARI (including 17 (61%) who subsequently required dialysis) whereas 35 had an ATLS-related ARI (including 31 (89%) who required dialysis). Acute leukemia (n = 28) and lymphoma (n = 30) were the main malignancies. All patients had high tumor burdens. Hospital and 6-month mortality rates were significantly lower in patients without ARI (7% and 21%, respectively) than in the ATLS-related renal injury group (51% and 66%). After adjustment for acute disease severity, presence of ARI at ICU admission was associated with higher hospital mortality (odds ratio, 10.41; 95% confidence interval, 2.01–19.170; p = 0.005) and 6-month mortality (odds ratio, 5.61; 95% confidence interval, 1.64–54.66; p = 0.006), compared to patients without renal injury. Our study suggests that in patients with ATLS, ICU management when acute renal injury is present is associated with higher short- and long-term mortality.

Acknowledgments

The authors thank A. Wolfe MD for helping with this manuscript. Financial support consisted of a grant from the Assistance Publique-Hôpitaux de Paris (CRC 07 011), a nonprofit government-funded organization; and a grant from the French Society for Intensive Care (SRLF), a nonprofit learned society in France.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.